UniProtKB/Swiss-Prot Q9H3D4: Variant p.Cys345Arg

Tumor protein 63
Gene: TP63
Chromosomal location: 3q27-q29
Variant information

Variant position:  345
The position of the amino-acid change on the UniProtKB canonical protein sequence.

Type of variant:  Disease [Disclaimer]
The variants are classified into three categories: Disease, Polymorphism and Unclassified.
  • Disease: Variants have been found in patients and disease-association is reported in literature. However, this classification is not a definitive assessment of variant pathogenicity.
  • Polymorphism: No disease-association has been reported.
  • Unclassified: Variants have been found in patients but disease-association remains unclear.

Residue change:  From Cysteine (C) to Arginine (R) at position 345 (C345R, p.Cys345Arg).
Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.

Physico-chemical properties:  Change from medium size and polar (C) to large size and basic (R)
The physico-chemical property of the reference and variant residues and the change implicated.

BLOSUM score:  -3
The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page

Variant description:  In EEC3; abolishes transcription activation.
Any additional useful information about the variant.



Sequence information

Variant position:  345
The position of the amino-acid change on the UniProtKB canonical protein sequence.

Protein sequence length:  680
The length of the canonical sequence.

Location on the sequence:   VTLETRDGQVLGRRCFEARI  C ACPGRDRKADEDSIRKQQVS
The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.

Residue conservation: 
The multiple alignment of the region surrounding the variant against various orthologous sequences.

Human                         VTLETRDGQVLGRRCFEARICACPGRDRKADEDSIRKQQVS

Mouse                         VTLETRDGQVLGRRCFEARICACPGRDRKADEDSIRKQQVS

Rat                           VTLETRDGQVLGRRCFEARICACPGRDRKADEDSIRKQQVS

Sequence annotation in neighborhood:  
The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.

TypePositionsDescription
Chain 1 – 680 Tumor protein 63
DNA binding 170 – 362


Literature citations

Heterozygous germline mutations in the p53 homolog p63 are the cause of EEC syndrome.
Celli J.; Duijf P.H.G.; Hamel B.C.J.; Bamshad M.; Kramer B.; Smits A.P.T.; Newbury-Ecob R.; Hennekam R.C.M.; Van Buggenhout G.; van Haeringen A.; Woods C.G.; van Essen A.J.; de Waal R.; Vriend G.; Haber D.A.; Yang A.; McKeon F.; Brunner H.G.; van Bokhoven H.;
Cell 99:143-153(1999)
Cited for: VARIANTS EEC3 TRP-243; GLN-243 AND ARG-345;

p63 gene mutations in EEC syndrome, limb-mammary syndrome, and isolated split hand-split foot malformation suggest a genotype-phenotype correlation.
van Bokhoven H.; Hamel B.C.J.; Bamshad M.; Sangiorgi E.; Gurrieri F.; Duijf P.H.G.; Vanmolkot K.R.J.; van Beusekom E.; van Beersum S.E.C.; Celli J.; Merkx G.F.M.; Tenconi R.; Fryns J.-P.; Verloes A.; Newbury-Ecob R.A.; Raas-Rotschild A.; Majewski F.; Beemer F.A.; Janecke A.; Chitayat D.; Crisponi G.; Kayserili H.; Yates J.R.W.; Neri G.; Brunner H.G.;
Am. J. Hum. Genet. 69:481-492(2001)
Cited for: VARIANTS EEC3 GLN-243; TRP-243; GLN-266; TYR-308; ASN-311; CYS-318; HIS-318; GLN-318; CYS-319; HIS-319; SER-319; TRP-343; GLN-343; ARG-345; SER-347; SER-348 AND HIS-351; VARIANTS SHFM4 PRO-193 INS; GLU-232 AND HIS-319; INVOLVEMENT IN LMS;

Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.